Every letter we have printed

Where an approach requires a clinician, saying so plainly is the most useful sentence in the piece. A great deal of published guidance in this area assumes access that many readers do not have, and pretending otherwise helps nobody.

Bacteriostatic preparations inhibit growth and do nothing about material already present. The word bacteriostatic is doing reassurance work in this market that its actual meaning does not support.

The recombinant factor C assay deserves a mention. It removes the reliance on a wild-harvested reagent, it is now recognised in more than one pharmacopoeia, and for a laboratory setting up new it is the sensible starting point. Your piece treats the lysate assay as the only option.

Your table of responses records four declines citing research-use-only status, and you call that a legally sound answer. It is also the answer that ends the conversation. What would you have a supplier say instead?

Badge and product are separated by a layer of navigation on most sites I visit. The badge sits in the footer, the product is on a different page, and the association a buyer draws between them is entirely their own work.

I would rather see no badge and a link reading "eleven reports, most recent April" than any mark currently in circulation. It is duller and it tells the reader the two things they actually need.

A suggestion for the services rather than for you: publish a price for a full package including the raw data files. I would pay it, my colleagues would pay it, and at present there is no line on any of the four price lists that lets me.

The most valuable custody artefact I have is a courier record showing a parcel held for six days at a hub in July. It explains a determination that would otherwise have looked like a manufacturing failure, and it cost nothing to obtain.

The retained-sample idea from an earlier letter belongs in this section too. If half the vial stays sealed with the buyer and half goes to the laboratory, a disputed result has a physical answer rather than a rhetorical one.

A phase-change pack and a frozen gel pack behave completely differently and are both described as cold packs. The first holds a temperature and the second holds a very low temperature briefly and then does nothing.

Loggers have become cheap enough that a supplier could include one in every carton for the cost of the outer box. The barrier is the willingness to generate a record that might be unflattering.

A stated storage condition without a supporting stability study is a recommendation rather than a finding, and the two look identical on a label. The question to ask is not what the storage condition is but what data it rests on, and the answer separates the trade quite sharply.

A temperature indicator that has not tripped tells you the parcel did not exceed a threshold for a duration. It does not tell you the parcel stayed cold, and the two readings are routinely confused by everybody including me until recently.

Documentation of the cold chain between the fill site and dispatch is the leg that is genuinely under the supplier’s control, and it is the one nobody asks about. Everything before the courier is theirs to describe.

A short letter to make one point. Nobody in this area distinguishes between stopping the substance and stopping the monitoring, and the second is at least as consequential. People who continue without measuring anything have made a different decision from people who stopped.

Discontinuation for a good reason and discontinuation for a bad one are recorded identically in most datasets. Somebody who stopped because they had reached what they wanted and somebody who stopped because they could not tolerate it appear in the same bar of the same chart.

A publication that covers a supply chain has something to say about maintenance that a clinical publication cannot: the arrangement depends on a company continuing to exist, continuing to make the same thing and continuing to ship it. None of those is guaranteed over a decade.

As a prescriber I would push back on your framing of the maintenance gap. We are not practising without evidence; we are practising on pharmacological inference, which is what clinicians do in every field where the trial has not been run. Calling it unevidenced makes reasonable practice sound reckless.

Buyers could create accountability tomorrow by asking for it. A purchase order that makes the certificate a term of the contract changes the position entirely, and it takes one sentence. The absence is a habit rather than a barrier.

The section on who stands behind the page should mention the second signature. In a quality system the analyst performs and a reviewer approves, and the two are different people for a reason. A certificate carrying one name is a record; a certificate carrying two is a record that has been checked.

A small format complaint. Reports that state a mass to four decimal places and an error in parts per million, without stating the mass at which the calibration was performed, are precise about the wrong thing. Precision presented without its provenance reads as authority and is not.

The value I most want on an identity report is the theoretical mass the analyst calculated, printed beside the observed one. Half the reports I receive give only the observed figure, which requires the reader to redo the arithmetic and to guess which charge state and which counter-ion the analyst assumed.

Syringes marked to fifty units exist and hold half a millilitre, with the same numbering scale. Somebody who has learned the arithmetic on a hundred-unit barrel and then picks up a fifty will get the volume right and the assumption wrong. It is worth a warning line.

Rounding conventions differ between calculators and the differences are not trivial at small volumes. Two tools given identical inputs will return different answers, and neither will say which convention it used.

The section on in-use stability is unhelpfully agnostic. Everyone in this market uses a figure of around thirty days refrigerated. Surely you can say whether that is roughly right rather than declining to comment.

A unit is not a dose and the word does the damage. It is a mark on a barrel. What it corresponds to in milligrams depends entirely on the concentration in the vial, and two people using the same mark on the same syringe can be drawing quantities that differ several-fold.

The material this publication covers is not approved for human use in any jurisdiction, which changes what a safety discussion can even mean. A pharmacovigilance system attaches to an approved product and there is no analogous system here at all.

Spontaneous reporting systems undercount by a factor nobody can pin down, and the databases are used in public argument as though they were registries. A note on what a voluntary reporting system can and cannot support would be a useful reference entry.

Pooled analyses across trials with different collection methods produce a number that describes no study, and they are the source of most widely quoted figures in this area. The pooling is legitimate and the resulting precision is illusory.

A note on species differences. The rodent work that established much of the mechanistic account uses receptor densities and transit times that differ markedly from human ones, and the translation is usually asserted rather than argued.

The follow-up periods in this literature are shorter than the periods people are planning for by a factor of several, and that ratio deserves to be printed rather than described. Two years of evidence against a ten-year intention is a number, not an impression.

Nothing in this area is settled enough to plan a decade around, and a great deal of the discussion I read assumes it is. Your department’s habit of stating the length of the evidence base alongside its findings is the most useful thing in it.

Continued lifestyle support in the withdrawal arm is a design choice that changes the result substantially, and studies differ on it. Comparing two withdrawal trials without checking that detail is comparing two different experiments.

Every long arrangement eventually meets a life event that interrupts it — a move, an illness, a change of circumstances. The literature treats interruption as non-adherence; the accounts I read treat it as ordinary life, and the two vocabularies describe the same events.

The lyophilisation step is sometimes described as though it sterilised the material. It does not; it removes water, and organisms and their fragments survive it routinely.

Where a supplier does test, ask for the limit against which the result was judged and who set it. A pass against an internally chosen limit is a statement about that limit as much as about the material.

The silence is not a conspiracy. It is what happens when nobody has an obligation, nobody has a question and the instrument that would answer it sits in a different laboratory from the one everybody already uses.

Research-use framing lets the whole question be avoided legitimately. Material sold for laboratory use has no requirement of this kind attached to it, and the framing is accurate as well as convenient.

Container closure integrity is the quiet half of this subject. A perfectly filled vial with a poorly seated stopper is not a sterile product a month later, and nothing on any document describes the seal. A crimp that turns under finger pressure is a finding a buyer can make without any instrument at all.

There is a version of this market with a certification tier, where a supplier pays for a fuller panel and is listed separately. It has not emerged, and it is worth asking why nobody has attempted it.